|
|
|
22.07.26 - 23:51
|
XETR: DIVIDEND/INTEREST INFORMATION - 24.07.2026 - US7170811035 (XETRA)
|
|
|
Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 23.07.2026 und ex Dividende/Zinsen am 24.07.2026
The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 23.07.2026 and its ex-dividend/interest day on 24.07.2026...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.26 - 18:30
|
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King (24/7 Wall St.)
|
|
|
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike. JNJ raised guidance while headlines fixated on a 68,000-case talc litigation MDL. Pfizer reaffirmed its outlook and pushed harder into obesity and oncology. Two large-cap dividend payers, two very different setups for buyers today. ... Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King...
|
|
|
|
|
|
|
|
|
14.07.26 - 17:54
|
Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen (24/7 Wall St.)
|
|
|
Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch. Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer's oncology ... Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen...
|
|
|
|
|
14.07.26 - 15:03
|
Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design (Business Wire)
|
|
|
Round led by Index Ventures, alongside Kleiner Perkins, Sequoia Capital, Dimension and existing investors, values company at $3.8B
Chai's AI models generate new molecular designs from scratch, helping partners including Eli Lilly and Pfizer pursue targets that traditional discovery methods struggle to reach
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.
The round, which values the company at $3.8B, was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital and Dimension.
These firms were joined by new investors Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, and other notable investors. Existing investors Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite also joined the round.
Chai Discovery builds AI models to accelerate pre-clinical drug di...
|
|
|
14.07.26 - 12:06
|
Germany Stops Recommending COVID-19 Vaccination For Most People Under 75 (ZeroHedge)
|
|
|
Germany Stops Recommending COVID-19 Vaccination For Most People Under 75
Authored by Zachary Stieber via The Epoch Times,
Germany has updated its COVID-19 vaccination recommendations, advising most people under 75 not to receive a COVID-19 vaccine.
A health worker at a mobile COVID-19 vaccination station in a shopping mall fills a syringe with the Pfizer-BioNTech vaccine in Ludwigsburg, Germany, on Nov. 11, 2021. Thomas Kienzle/AFP via Getty Images
Germany's Standing Committee on Vaccination, which offers vaccine recommendations for the country, on July 9 said in a 33-page document that its stance on COVID-19 vaccination was changing "to reflect the current epidemiological situation and the population's immune status."
The committee, known as STIKO, added: "A large proportion of the adult population now has hybrid immunity, characterised by exposure to a variety of antigenic contacts, and is therefore sufficiently well protected against severe cases of COVID-19.
"This als...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
